ClinicalTrials.gg
CompletedNCT01288742Updated Nov 30, 2012

TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Digoxin and Between TMC435 and Rosuvastatin

A Phase 1 interventional study of Rosuvastatin and Rosuvastatin in Hepatitis C Virus, sponsored by Tibotec Pharmaceuticals, Ireland. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-11-30.

Sponsored by Tibotec Pharmaceuticals, Ireland (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing simeprevir in Hepatitis C — none open to participants now, none under way, none of them phase 3. Simeprevir · Hepatitis C.

Enrollment
32nd of 50
33 · median 49
Started
2011
with 14 others
Phase 1
25 of 50
none open now
Registered
23rd of 50
by date
Lead sponsor
25 of 50
Tibotec Pharmaceuticals, Ireland

Among the 50 studies testing simeprevir in Hepatitis C, this one is the 32nd largest by enrollment, is one of 15 that started in 2011, is one of 25 in phase 1, and was the 23rd registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 50 studies testing simeprevir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About simeprevir

Simeprevir: first FDA approval 2013 (OLYSIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies testing simeprevir in Hepatitis C as a file.
02

Study summary

The purpose of this study is to investigate the effect of steady-state concentrations of TMC435 on the single-dose pharmacokinetics of digoxin or rosuvastatin , and the effect of a single dose of digoxin or rosuvastatin on the steady-state pharmacokinetics of TMC435. Steady state is a term that means that the drug has been given long enough so that the plasma concentrations will remain the same with each subsequent dose. TMC435 is being investigated for the treatment of chronic hepatitis C virus (HCV) infection. Pharmacokinetics (PK) means how the drug is absorbed into the bloodstream, distributed in the body, and eliminated from the body.

Read the detailed description

TMC435 is being investigated for treatment of chronic hepatitis C virus (HCV) infection, in combination with Peg-IFN (pegylated interferon) and RBV (ribavirin). Digoxin and rosuvastatin are expressed in the liver and intestine and mediate the transport of drugs out of the blood circulation. The result of this study will provide dosing recommendations for TMC435 and for digoxin, rosuvastatin, or other substrates using the same drug transporter molecules, when being coadministered. This is a Phase I, open-label (both participant and investigator know the name of the medication given at certain moment), randomized (sequence of treatment with study medications is assigned by chance), crossover trial in 32 healthy volunteers to investigate the pharmacokinetic interaction between TMC435, at steady state, and digoxin or rosuvastatin at a single dose. The volunteers will be allocated to one of two panels. In Panel 1, volunteers will receive two treatments (Trts A and B) in a randomized order. Volunteers will receive digoxin 0.25 mg once daily for 1 day (Trt A) and TMC435 150 mg once daily for 7 days (Trt B) and 0.25 mg digoxin once daily for 1 day (Trt B). In Panel 2, volunteers will receive two treatments (Trts C and D) in a randomized order. Volunteers will receive rosuvastatin 10 mg once daily for 1 day (Trt C) and TMC435 150 mg once daily for 7 days (Trt D) and rosuvastatin 10 mg once daily for 1 day (Trt D). In both panels, there will be a washout period (a period when no study drug will be taken, in order to have all the medication eliminated from the body before starting a new treatment) of at least 14 days between last intake of the study medication in one session and the first intake of study medication in the subsequent session. Pharmacokinetic profiles of all three compounds will be determined through blood samples taken at regular intervals during the study. Safety and tolerability will be assessed during the study period and during follow up. Blood and urine samples, electrocardiogram (ECG) and vital signs (blood pressure and heart rate) will be taken at screening, before medication intake on Day -1 or Day 1 (Trts A, B, C, and D), on Day 2 (Trts A and C), before medication intake and 6 hours postdose (only vital signs and ECG) on Day 7 (Trts B and D), on Day 8 (Trts B and D) and at the 2 follow up visits at 1 week and 4-5 weeks after last dose of study medication in the last session. A physical examination will be performed at screening, on Day -1 (= day before first medication intake in each session for both panels) and on Day 2 in Trts A and C, on Day -1 and on Day 8 of Trts B and D and during the 2 follow-up visits. Each volunteer is part of one panel and follows 2 treatment (Trt) periods, which are a minimum 14 days apart from each other. Trt period for Trts A and C - 5 days; Trt period for Trts B and D - 11 days. Trt A and B = Panel 1, Trt C and D = Panel 2. A single, oral dose of digoxin (0.25 mg) or rosuvastatin (10 mg) to be given in Trt A or Trt C, respectively. Multiple doses of TMC435 (150 mg) for 7 days to be given in TrtB and D, with a single dose of digoxin or rosuvastatin on Day7, respectively.

03

Conditions studied

  • Hepatitis C Virus

Browse trials for

Keywords

  • TMC435-TiDP16-C108
  • TMC435-C108
  • TMC435
  • HPC
  • HCV
  • Hepatitis C
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-smoker or not having chewed tobacco for at least 6 months
  • of 18.0 to 30.0 kg/m2
  • Healthy based on a medical evaluation including medical history, physical examination, blood tests, vital signs, and

Exclusion criteria

Exclusion Criteria:

  • Infection with hepatitis A, B or C virus
  • Infection with the (HIV)
  • History of, or any current medical condition which could impact the safety of the participant in the study
  • Having previously participated in a multiple-dose trial with TMC435
  • Having previously participated in more than 3 single-dose trials with TMC435
  • History of rhabdomyolysis or other muscle abnormalities upon statin intake (Panel 2).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    001

    TMC435 One 150-mg capsule once daily for 7 days (Trts B and D).

    Drug: TMC435

  • Experimental
    002

    Digoxin One 0.25-mg tablet for 1 day (Trt A)

    Drug: Digoxin

  • Experimental
    003

    Digoxin One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.

    Drug: Digoxin

  • Experimental
    004

    Rosuvastatin One 10-mg tablet for 1 day (Trt C).

    Drug: Rosuvastatin

  • Experimental
    005

    Rosuvastatin One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.

    Drug: Rosuvastatin

Interventions

  • One 10-mg tablet for 1 day (Trt C).

  • One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.

  • DrugTMC435

    One 150-mg capsule once daily for 7 days (Trts B and D).

  • One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.

  • One 0.25-mg tablet for 1 day (Trt A)

06

What researchers measure

Primary outcomes

  1. Change in absorption of TMC435 following co-administration with Digoxin (Panel 1).

    Time frame: Measured on Days 1, 5-11 (Trt B). Reference for TMC435 is from historical data.

  2. Change in absorption of Digoxin following co-administration with TMC435 (Panel 1).

    Time frame: Measured on Day 7-11 (Trt B). Reference for Digoxin is on Day 1-5 of Trt A.

  3. Change in absorption of TMC435 following co-administration with rosuvastatin (Panel 2).

    Time frame: Measured on Day 1, 5-11 (Trt D). Reference for TMC435 are historical data.

  4. Change in absorption of rosuvastatin following co-administration with TMC435 (Panel 2).

    Time frame: Measured on Day 7-11 (Trt D). Reference for rosuvastatin is on Days 1-5 of Trt C.

Secondary outcomes

  1. Number of participants with adverse events as a measure of safety and tolerability - TMC435 and Digoxin

    Time frame: 51 to 56 days (until and including last safety follow-up visit) for Panel 1

  2. Number of participants with adverse events as a measure of safety and tolerability - TMC435 and rosuvastatin

    Time frame: 51 to 56 days (until and including last safety follow-up visit) for Panel 2

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2011
First posted
Feb 2, 2011
Start
Jan 2011
Primary completionActual
May 2011
CompletionActual
May 2011
Last update
Nov 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01288742
Responsible party
Sponsor
First posted
Feb 2, 2011
Start date
Jan 2011
Primary completion
May 2011
Completion
May 2011
Last update
Nov 30, 2012

Study contacts

Tibotec Pharmaceuticals Clinical Trial
study director · Tibotec Pharmaceutical Limited
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Simeprevir · Digoxin

Start the discussion